Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 4 N=7 Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
N/A N=20 Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 4 N=70 Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Atopic Dermatitis · Secondary Infection
Primary: Bacteriological Culture — 13; 3; 16; 5 participants
Phase 2 N=20 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Secondarily Infected Traumatic Lesions (SITL) · Impetigo
Primary: TD1414 Serum Concentration by Timepoint — 624.3; 864.1; 1195.7; 888.4 pg/mL
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
N/A N=148 ObservAtional Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers
Skin Cancer
Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants
Phase 2 N=65 Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Impetigo · Secondarily Infected Traumatic Lesions
Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants
Phase 2 N=47 Tofacitinib for Immune Skin Conditions in Down Syndrome
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
N/A N=95 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Zika · Dengue · Malaria
Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…
N/A N=465 The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care
Decision Support Systems,Clinical · Skin Diseases
Primary: Number of Patients With Resolved Skin Problems — 72; 135 Participants — p=0.54
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 1 N=15 Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Atopic Dermatitis Eczema
Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus
N/A N=50 Spread of Dermatophytes Among Families
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates
Phase 4 N=17 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema
Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
N/A N=35 Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
Healthy Volunteers
Primary: Microbial Community Richness - Baseline (Day 0) — 56.5862069; 32.13043478; 43.72413793; 34.03703704 Number of bacterial taxa — p=0.071225
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
N/A N=2 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
Phase 4 N=101 Skin and Soft Tissue Infection (SSTI) Study
Skin Diseases, Infectious · Soft Tissue Infections
Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 4 N=31 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score